Published On : August 2026
Ask ten packaging engineers which printing technology is best and you will likely get ten different answers, because the honest answer depends entirely on run length, substrate, and whether the product line requires serialized, variable data. Mexico's pharmaceutical packaging printing industry runs on four core technologies, each suited to a distinct combination of volume, format and compliance requirement, and understanding those trade-offs is the starting point for any packaging or sourcing decision.
Pharmaceutical converters in Mexico typically operate one or more of four press technologies: offset, flexographic, digital and gravure. Each brings a different balance of setup cost, run-length economics and print capability, which is why most mid-sized and large suppliers maintain a mixed fleet rather than standardizing on a single technology.
This production-side view sits alongside the broader Mexico pharmaceutical packaging printing market outlook, which quantifies how these technologies and formats contribute to overall market size and growth.
Technology selection is rarely a one-time decision. As a pharma manufacturer's product mix shifts, from stable long-run generics toward serialized, export-compliant, or short-run specialty products, the printing technology required to support that mix shifts with it. Converters that can flex across formats without re-tooling entire production lines hold a structural advantage in retaining accounts through this kind of transition.
Investment patterns across the converter base reflect this reality. Purchasing decisions for new press capacity increasingly weigh a technology's ability to handle tomorrow's compliance requirements, not just today's carton or label order, which is why digital and hybrid configurations are commanding a growing share of new capital expenditure even where offset and flexographic capacity remains fully utilized on existing accounts.
Offset lithography remains the workhorse technology for high-volume folding cartons and labels where design content stays constant across long production runs. Its economics improve as run length increases, since setup and plate costs are amortized over a larger unit volume, making it the natural choice for established generics and OTC products with stable packaging artwork.
Offset's principal limitation is inflexibility. Because it requires physical plates for each print job, introducing variable data, unique serial numbers, batch codes, or region-specific text, on an offset line typically means adding a secondary in-line printing or coding station rather than handling it natively within the press itself. This is the central reason offset, despite its cost advantages, cannot alone satisfy modern serialization mandates without supplementary equipment.
Color and finish consistency remain offset's other enduring strength. Pharma brand owners rely on tight color tolerances to maintain shelf recognition across large production volumes, and offset's plate-based process delivers that consistency more reliably across a multi-month production run than digital alternatives can currently match at comparable cost. This is why offset retains its position as the largest technology segment even as compliance-driven demand shifts incrementally toward digital capacity.
Flexographic printing uses flexible relief plates and fast-drying inks, making it well suited to labels and blister lidding films that need to withstand handling, moisture and, in some cases, cold-chain conditions. Flexo's ability to print on a wide range of substrates, including foils and films used in blister packaging, gives it a durability advantage that offset cannot match for these specific formats.
Changeover speed is another practical advantage. Flexo presses can switch between label jobs faster than offset lines can reconfigure for a new carton run, which matters for converters serving multiple small and mid-sized pharma customers who order in shorter batches than large multinational manufacturers typically do.
Ink chemistry has also evolved specifically to serve pharma applications. UV-curable and water-based flexo inks now meet the migration and food-contact-adjacent safety standards that pharmaceutical labeling and blister lidding require, closing what was once a quality gap between flexo and higher-cost alternatives. That improvement has widened flexo's addressable range within the pharma segment over the past several production cycles.
Digital printing has become the technology of choice wherever a packaging job requires variable data, unique serial numbers, lot codes, expiry dates, or region-specific language, printed without slowing the production line or requiring new plates for every change. This capability makes digital presses the natural production-side answer to serialization and track-and-trace mandates.
Digital printing's role here connects directly to serialization and track-and-trace compliance requirements, since regulatory mandates for unit-level traceability are one of the primary forces expanding digital adoption across Mexico's pharma converting base faster than any other printing technology.
Short-run economics are digital's other defining strength. A converter printing a limited batch for a clinical trial, a new product launch, or a small nutraceutical brand can do so without the plate costs that would make offset or gravure impractical for the same volume. This makes digital increasingly attractive not just for compliance printing but for the growing base of smaller and specialty pharma customers entering the market.
Print quality on digital presses has closed much of the gap with offset over recent equipment generations, though very high-volume, long-run jobs still tend to favor offset on a pure cost-per-unit basis. The practical outcome is a division of labor rather than outright displacement: digital captures the growing share of work that carries a compliance or variable-data requirement, while offset continues to serve stable, high-volume runs where that requirement does not apply.
Gravure printing, using engraved cylinders that hold ink in etched cells, delivers the highest print fidelity of the four core technologies and remains the preferred choice for high-end packaging applications where color consistency and image detail across very long runs justify its higher upfront cylinder cost. In pharma packaging, this typically means premium OTC and specialty product lines where shelf appearance carries commercial weight.
Gravure's economics mirror offset's in one important respect: both technologies favor long, stable runs and penalize frequent design changes. As a result, gravure capacity in Mexico tends to be concentrated among larger converters serving established brand portfolios rather than smaller or short-run customers.
Because cylinder engraving is a significant upfront investment, gravure work in the pharma segment is typically reserved for flagship OTC brands and premium specialty products where the cost is justified by production volume and brand visibility, rather than for standard generic packaging where offset delivers comparable quality at lower setup cost.
Folding cartons serve as the primary secondary-packaging format across most pharma product categories, typically printed via offset or, increasingly, digital for serialized lines. Labels, spanning pressure-sensitive, shrink-sleeve and in-mold formats, are most commonly produced via flexographic or digital printing depending on run length and variable-data requirements.
Leaflets and inserts, the multi-language compliance documents required for many export-oriented and complex products, are generally digitally printed given their need for frequent content updates and relatively short print runs per language variant. Blister packaging printing, covering both forming webs and lidding foils, relies heavily on flexographic technology for its durability on foil and film substrates.
Flexible packaging, including sachets and pouches, is closely tied to the pharmaceutical product categories driving packaging demand, since this format is disproportionately used for nutraceutical and powdered-formulation products rather than traditional solid-dose pharmaceuticals.
A useful starting framework for packaging engineers is to separate the decision into two questions: does this format require variable data, and does the expected run length justify plate or cylinder setup costs? Long-run, static-content cartons and premium labels favor offset or gravure. Any format requiring serialization, batch-specific coding or short runs favors digital. Foil and film-based formats, blister lidding and forming webs in particular, favor flexographic printing regardless of run length, given the substrate durability requirement.
In practice, most converters serving the pharma sector maintain capability across at least three of the four technologies, since few customers request a single format exclusively across their full product portfolio. The suppliers gaining share fastest are those investing in digital capacity specifically, since that is where compliance-driven demand growth is concentrated.
For packaging engineers evaluating a new supplier, a practical due-diligence question is not simply which technologies a converter operates, but how quickly they can move a given product between formats as its compliance profile changes over its lifecycle, since that flexibility, more than any single piece of equipment, determines long-term supply continuity.